Candesartan and renal protection: more than blocking angiotensin type 1 receptor?
Chen et al. show that candesartan (Cand) displays an antioxidant action independent of angiotensin type 1 receptor (AT1R) blockade that translates into a superior renoprotection of chronic renal inflammation. The peculiarity of Cand in combining AT1R-blocking activity and an antioxidant action could have important theoretical implications for therapy.
Mario Negri Institute for Pharmacological Research, Bergamo, Italy.
Daniela
D
Macconi
Giuseppe
G
Remuzzi
D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology; D000975:Antioxidants / Q000494:pharmacology; D001562:Benzimidazoles / Q000494:pharmacology*; D001713:Biphenyl Compounds; D006801:Humans; D007249:Inflammation / Q000517:prevention & control; D007674:Kidney Diseases / Q000473:pathology / Q000517:prevention & control*; D020011:Protective Agents / Q000494:pharmacology; D013777:Tetrazoles / Q000494:pharmacology*
D047228:Angiotensin II Type 1 Receptor Blockers; D000975:Antioxidants; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D020011:Protective Agents; D013777:Tetrazoles; C081643:candesartan